NOVAVAX INC(FRA:NVV1) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to NVV1. NVV1 was compared to 72 industry peers in the Biotechnology industry. Both the profitability and financial health of NVV1 have multiple concerns. NVV1 does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NVV1 has reported negative net income.

NVV1 had a negative operating cash flow in the past year.

In the past 5 years NVV1 always reported negative net income.

NVV1 had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of NVV1 (-16.63%) is better than 60.94% of its industry peers.

		Industry Rank	Sector Rank
ROA	-16.63%
ROE	N/A
ROIC	N/A

ROA(3y)-42.37%

ROA(5y)-46.05%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NVV1 has a better Gross Margin (63.79%) than 62.50% of its industry peers.

The Profit Margin and Operating Margin are not available for NVV1 so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	63.79%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NVV1 does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, NVV1 has more shares outstanding

The number of shares outstanding for NVV1 has been increased compared to 5 years ago.

The debt/assets ratio for NVV1 has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -3.76, we must say that NVV1 is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -3.76, NVV1 is doing worse than 67.19% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-3.76

ROIC/WACCN/A

WACC9.99%

2.3 Liquidity

NVV1 has a Current Ratio of 0.93. This is a bad value and indicates that NVV1 is not financially healthy enough and could expect problems in meeting its short term obligations.

The Current ratio of NVV1 (0.93) is worse than 75.00% of its industry peers.

A Quick Ratio of 0.93 indicates that NVV1 may have some problems paying its short term obligations.

NVV1's Quick ratio of 0.93 is on the low side compared to the rest of the industry. NVV1 is outperformed by 70.31% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.93
Quick Ratio	0.93

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NVV1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.52%, which is quite impressive.

NVV1 shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.68%.

NVV1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 95.67% yearly.

EPS 1Y (TTM)64.52%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.68%

Revenue 1Y (TTM)-15.68%

Revenue growth 3Y27.41%

Revenue growth 5Y95.67%

Sales Q2Q%-54.81%

3.2 Future

NVV1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.98% yearly.

The Revenue is expected to decrease by -12.75% on average over the next years. This is quite bad

EPS Next Y76.48%

EPS Next 2Y42.12%

EPS Next 3Y29.51%

EPS Next 5Y17.98%

Revenue Next Year-28.64%

Revenue Next 2Y-25.89%

Revenue Next 3Y-13.71%

Revenue Next 5Y-12.75%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NVV1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

With a Price/Forward Earnings ratio of 76.99, NVV1 can be considered very expensive at the moment.

NVV1's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NVV1 is cheaper than 78.13% of the companies in the same industry.

NVV1's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 92.74.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	76.99

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NVV1's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

NVV1's earnings are expected to grow with 29.51% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y42.12%

EPS Next 3Y29.51%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NVV1!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NOVAVAX INC

FRA:NVV1 (2/4/2025, 7:00:00 PM)

8.105

-0.11 (-1.3%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-12 2024-11-12/bmo

Earnings (Next)N/A N/A

Inst Owners54.64%

Inst Owner ChangeN/A

Ins Owners0.3%

Ins Owner ChangeN/A

Market Cap1.30B

Analysts76.67

Price Target17.29 (113.33%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-17.4%

Min EPS beat(2)-40.73%

Max EPS beat(2)5.92%

EPS beat(4)2

Avg EPS beat(4)-61.61%

Min EPS beat(4)-214.89%

Max EPS beat(4)5.92%

EPS beat(8)5

Avg EPS beat(8)-26.55%

EPS beat(12)5

Avg EPS beat(12)-98.18%

EPS beat(16)6

Avg EPS beat(16)-79.7%

Revenue beat(2)1

Avg Revenue beat(2)0.58%

Min Revenue beat(2)-11.17%

Max Revenue beat(2)12.33%

Revenue beat(4)1

Avg Revenue beat(4)-4.79%

Min Revenue beat(4)-11.29%

Max Revenue beat(4)12.33%

Revenue beat(8)3

Avg Revenue beat(8)6.57%

Revenue beat(12)4

Avg Revenue beat(12)-4.95%

Revenue beat(16)5

Avg Revenue beat(16)-3.39%

PT rev (1m)0.96%

PT rev (3m)-13.51%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-182.78%

EPS NY rev (1m)10.63%

EPS NY rev (3m)-57.89%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-76.41%

Revenue NY rev (1m)5.85%

Revenue NY rev (3m)-4.91%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	76.99
P/S	1.52
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-2.19

EYN/A

EPS(NY)0.11

Fwd EY1.3%

FCF(TTM)-0.67

FCFYN/A

OCF(TTM)-0.55

OCFYN/A

SpS5.35

BVpS-3.18

TBVpS-3.95

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-16.63%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	63.79%
FCFM	N/A

ROA(3y)-42.37%

ROA(5y)-46.05%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.52

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	42.72%
Cap/Sales	2.26%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.93
Quick Ratio	0.93
Altman-Z	-3.76

F-Score4

WACC9.99%

ROIC/WACCN/A

Cap/Depr(3y)300.93%

Cap/Depr(5y)410.08%

Cap/Sales(3y)5.06%

Cap/Sales(5y)7.36%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)64.52%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.68%

EPS Next Y76.48%

EPS Next 2Y42.12%

EPS Next 3Y29.51%

EPS Next 5Y17.98%

Revenue 1Y (TTM)-15.68%

Revenue growth 3Y27.41%

Revenue growth 5Y95.67%

Sales Q2Q%-54.81%

Revenue Next Year-28.64%

Revenue Next 2Y-25.89%

Revenue Next 3Y-13.71%

Revenue Next 5Y-12.75%

EBIT growth 1Y52.65%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year71.76%

EBIT Next 3Y27.97%

EBIT Next 5YN/A

FCF growth 1Y84.77%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y85.82%

OCF growth 3YN/A

OCF growth 5YN/A

NOVAVAX INC (NVV1.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens